{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:18:14Z","timestamp":1784744294891,"version":"3.55.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Perampanel is a novel noncompetitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) glutamate receptor, which is approved as an adjunctive agent for the treatment of partial-onset seizure with or without secondary generalization and for primary generalized tonic-clonic seizure in patients with epilepsy who are at least 12 years of age. Limited information is available about the clinical utility of therapeutic drug monitoring of perampanel and therapeutic ranges are so far not established. Therefore, perampanel titration should be performed especially in case of insufficient success of the drug.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The authors developed a selective and sensitive LC-MS\/MS (liquid chromatography-mass spectrometry) assay to monitor perampanel concentrations in plasma, which was compared to a commercially available high-performance liquid chromatography kit with fluorescent detection. Perampanel and the internal standard were extracted from plasma samples by a simple protein precipitation. The method allows the simultaneous quantification of perampanel and several other antiepileptic drugs (AEDs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Data were evaluated according to EMA guidelines for bioanalytical method validation. Extraction recovery of perampanel from human plasma was consistently above 98%. No matrix effect was found. Analytical interferences by other AEDs were not observed. The method was linear in the range from 2.5 to 2800 ng\/mL. Intra-assay and interassay reproducibility analyses demonstrated accuracy and precision within acceptance criteria. Data collected from 95 patients, given perampanel as their maintenance antiepileptic therapy, showed a very strong correlation between the 2 methods.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The assay allows for highly sensitive and selective quantification of perampanel and concomitant AEDs in patient plasma samples and can be easily implemented in clinical settings. Our findings are in agreement with previously published data in patients comedicated with enzyme inducer AEDs, but seem to indicate a possible interaction in patients treated with the enzyme inhibitor drug valproic acid.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000531","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T02:38:02Z","timestamp":1525919882000},"page":"477-485","source":"Crossref","is-referenced-by-count":33,"title":["A Liquid Chromatography-Mass Spectrometry Assay for Determination of Perampanel and Concomitant Antiepileptic Drugs in the Plasma of Patients With Epilepsy Compared With a Fluorescent HPLC Assay"],"prefix":"10.1097","volume":"40","author":[{"given":"Ugo","family":"de Grazia","sequence":"first","affiliation":[{"name":"Clinical Pathology and Medical Genetics Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annachiara","family":"D'Urso","sequence":"additional","affiliation":[{"name":"Clinical Pathology and Medical Genetics Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ranzato","sequence":"additional","affiliation":[{"name":"Epilepsy Centre, Neuroscience Department, S. Bortolo Hospital; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"De Riva","sequence":"additional","affiliation":[{"name":"Neurobiology Laboratory, Neuroscience Department, S. Bortolo Hospital, Vicenza, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Contarato","sequence":"additional","affiliation":[{"name":"Neurobiology Laboratory, Neuroscience Department, S. Bortolo Hospital, Vicenza, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Billo","sequence":"additional","affiliation":[{"name":"Epilepsy Centre, Neuroscience Department, S. Bortolo Hospital; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Perini","sequence":"additional","affiliation":[{"name":"Epilepsy Centre, Neuroscience Department, S. Bortolo Hospital; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Galloni","sequence":"additional","affiliation":[{"name":"Neurobiology Laboratory, Neuroscience Department, S. Bortolo Hospital, Vicenza, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","first-page":"683","article-title":"Perampanel (Fycompa) a review of clinical efficacy and safety in epilepsy","volume":"41","author":"Greenwood","year":"2016","journal-title":"P T."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2012.12.006","article-title":"Novel treatment options for epilepsy: focus on perampanel","volume":"70","author":"Franco","year":"2013","journal-title":"Pharmacol Res."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/epi.12240","article-title":"Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures","volume":"54","author":"Gidal","year":"2013","journal-title":"Epilepsia."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/FTD.0000000000000274","article-title":"Perampanel serum concentration in adult with epilepsy: effect of dose, age, gender and concomitant antiepileptic drugs","volume":"38","author":"Patsalos","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R9-20230814","first-page":"293","article-title":"Determinazione della concentrazione plasmatica di perampanel, Proceeding of 22 annual Symposium of European Ligand Assay Society ELAS","volume":"21","author":"Galloni","year":"2016","journal-title":"Ligand Assay"},{"key":"R11-20230814","first-page":"S96","article-title":"Therapeutic drug monitoring of perampanel in human samples: a novel LCMS\/MS assay compared with a fluorescent HPLC assay, proceeding of 49 Congresso Societ\u00e0 Italiana di Biochimica Clinica SIBIOC, Firenze (Italy) 16-18 October 2017","volume":"41","author":"D'Urso","year":"2017","journal-title":"Biochimica Clinica"},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal Chem."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/FTD.0000000000000416","article-title":"Therapeutic drug monitoring for perampanel in Japanese epilepsy patients: influence of concomitant antiepileptic drugs","volume":"39","author":"Yamamoto","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/bmc.3463","article-title":"HPLC with fluorescence detection assay of perampanel, a novel AMPA receptor antagonist, in human plasma for clinical pharmacokinetic studies","volume":"10","author":"Mano","year":"2015","journal-title":"Biomed Chromatogr."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jpba.2014.12.018","article-title":"High-performance liquid chromatography-tandem mass spectrometry method for the determination of perampanel, a novel \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist in human plasma","volume":"107","author":"Mano","year":"2015","journal-title":"J Pharm Biomed Anal."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/bmc.3764","article-title":"An inter-laboratory cross-validation study for the determination of perampanel in human plasma by liquid chromatography assays","volume":"30","author":"Mano","year":"2016","journal-title":"Biomed Chromatogr."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/FTD.0000000000000350","article-title":"Development and validation of an HPLC-UV assay for the therapeutic monitoring of the new antiepileptic drug perampanel in human plasma","volume":"38","author":"Franco","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.plabm.2017.11.003","article-title":"Simple and rapid validated HPLC-fluorescence determination of perampanel in the plasma of patients with epilepsy","volume":"10","author":"Mohamed","year":"2018","journal-title":"Pract Lab Med."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201808000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:17:14Z","timestamp":1692051434000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201808000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000531","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}